Susquehanna Fundamental Investments LLC Acquires New Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Susquehanna Fundamental Investments LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 56,585 shares of the biopharmaceutical company's stock, valued at approximately $13,315,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Tidal Investments LLC raised its position in shares of Alnylam Pharmaceuticals by 75.1% in the third quarter. Tidal Investments LLC now owns 20,544 shares of the biopharmaceutical company's stock valued at $5,650,000 after buying an additional 8,811 shares during the last quarter. American Trust purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth $309,000. Versant Capital Management Inc boosted its holdings in shares of Alnylam Pharmaceuticals by 77.6% during the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 83 shares during the last quarter. Everence Capital Management Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $593,000. Finally, Nordea Investment Management AB grew its position in shares of Alnylam Pharmaceuticals by 6.7% in the fourth quarter. Nordea Investment Management AB now owns 10,188 shares of the biopharmaceutical company's stock valued at $2,417,000 after purchasing an additional 637 shares during the period. Hedge funds and other institutional investors own 92.97% of the company's stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Wells Fargo & Company raised their price target on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a research note on Friday, March 21st. Canaccord Genuity Group boosted their target price on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a report on Friday, March 21st. William Blair reaffirmed an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $280.00 to $328.00 in a report on Monday, March 24th. Finally, Redburn Atlantic initiated coverage on Alnylam Pharmaceuticals in a report on Monday, March 31st. They set a "buy" rating and a $353.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $316.63.

Alnylam Pharmaceuticals Stock Up 1.2 %

Shares of Alnylam Pharmaceuticals stock traded up $3.10 during trading hours on Friday, hitting $258.23. 249,968 shares of the company's stock traded hands, compared to its average volume of 882,336. Alnylam Pharmaceuticals, Inc. has a twelve month low of $144.73 and a twelve month high of $304.39. The company has a market cap of $33.59 billion, a PE ratio of -119.00 and a beta of 0.30. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The stock has a 50 day simple moving average of $247.93 and a 200-day simple moving average of $255.50.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. The firm's revenue was up 20.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.16) EPS. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 967 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the transaction, the chief financial officer now owns 32,786 shares of the company's stock, valued at $8,366,003.62. This trade represents a 2.86 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the transaction, the executive vice president now owns 14,321 shares of the company's stock, valued at approximately $3,654,862.41. The trade was a 4.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 7,392 shares of company stock worth $1,875,627 in the last ninety days. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.